Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in L'hospitalet De Llobregat – page 299

3 655 clinical trials in L'hospitalet De Llobregat, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
L'hospitalet De Llobregat at a glance
3 655
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

3 655 trials in L'hospitalet De Llobregat

Open in trial search

Study on the Effect of Tamoxifen and Chemotherapy in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with Low Recurrence Scores

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Study Comparing Standard Chemotherapy with Letrozole and Abemaciclib for High/Intermediate Risk HR-Positive, HER2-Negative Breast Cancer Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Study of FOLFOX6m, Bevacizumab, and Irinotecan for Patients with Colorectal Cancer and Liver Metastases

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Grupo Espanol Multidisciplinar En Cancer Digestivo

Study of Olaparib and Durvalumab for Patients with Metastatic Pancreatic Cancer and DNA Repair Gene Alterations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Asociacion Grupo Tratamiento De Tumores Digestivos

Neoplasm

Not recruiting

Study on AloCelyvir with Chemotherapy and Radiotherapy for Children and Adolescents with Relapsed or Refractory Extracranial Solid Tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Sponsor:Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus

Angelman's syndrome

Not recruiting

Study on the Safety and Tolerability of Rugonersen in Patients with Angelman Syndrome

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Sponsor:F. Hoffmann-La Roche AG

Metastatic neoplasm

Not recruiting

Study on the Effectiveness of Tislelizumab and Spartalizumab in Patients with Advanced or Metastatic Cancer with High PD1 Biomarker Levels

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Spartalizumab
  • Sponsor:Solti Group

Systemic mastocytosis+1

Not recruiting

Study of Avapritinib for Patients with Indolent Systemic Mastocytosis Not Adequately Managed by Standard Therapy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Avapritinib
  • Sponsor:Blueprint Medicines Corp.

Plasma cell myeloma

Not recruiting

Study Comparing Selinexor, Pomalidomide, and Dexamethasone with Elotuzumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:European Myeloma Network B.V.

Neoplasm

Not recruiting

Study of MCLA-129 with Chemotherapy and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Genmab A/S

Study on Nemvaleukin Alfa and Pembrolizumab for Patients with Advanced Skin or Mucosal Melanoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nemvaleukin Alfa
  • Sponsor:Mural Oncology Inc.

Transplant rejection

Not recruiting

Study on Efgartigimod for Patients with Antibody-Mediated Rejection after Kidney Transplant

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in L'hospitalet De Llobregat

What the registry says about research in the country

01 Infectious Disease Prevention

Innovative research focused on vaccine development targeting multiple infectious diseases, including studies on UTI prevention, yellow fever, and RSV protection in adults.

  • UTI Vaccine Safety & Efficacy
  • Yellow Fever Immunization
  • RSV Protection Studies

These trials aim to enhance vaccine effectiveness and improve public health outcomes through preventive measures.

02 Oncology Research

Comprehensive studies exploring new treatments for various types of advanced cancers, with particular focus on targeted therapies and novel drug combinations.

  • Colorectal Cancer Treatment
  • Gastric Cancer Therapies
  • Pancreatic Cancer Interventions

Advanced clinical research investigating innovative approaches to combat various forms of cancer.

03 Transplant Medicine

Groundbreaking research in kidney transplantation, focusing on preventing rejection and improving post-transplant outcomes.

  • Antibody-Mediated Rejection
  • Delayed Graft Function
  • Novel Immunosuppressive Approaches

Studies aimed at enhancing transplant success rates and patient recovery.

04 Autoimmune Conditions

Clinical investigations into treatments for various autoimmune disorders, including innovative therapies for inflammatory conditions.

  • Psoriatic Arthritis Treatment
  • Atopic Dermatitis Management
  • Myasthenia Gravis Therapy

Focused on developing targeted treatments to improve patient quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.